CA17104 – STRATAGEM – NEW DIAGNOSTIC AND THERAPEUTIC TOOLS AGAINST MULTIDRUG RESISTANT TUMOURS

WG2 Hybrid Meeting in Angers (France)

"Synthesis and nanodelivery strategies for new therapeutic tools against Multidrug Resistant Tumours"

Monday, December 6th, 2021 – 9H to 12H CET

AGENDA

9H : Presentation of MINT laboratory (Inserm 1066, CNRS 6021 – Angers University) - Patrick Saulnier, director of MINT

9H10/9H45 : Update about WG2

1- WG2 members (introduction by Javier De Las Rivas)
2- Short introduction of new WG2 members
3- STSMs, ITC and ECI-related initiatives
4- Special Issues for CANCERS and DRU
5- Next meetings: WG3/4 Training School and Annual Meeting
6- Biosketches, keywords, ongoing collaborations
7- Website: https://stratagem-cost.eu/ (Yordan Yordanov)

9H45/10H : Coffee break - Posters

10H/12H : Scientific presentations

8- Database of compounds set up by WG1 leader (Thomas Mohr)
9- Scientific presentation of WG2 members

STRATAGEM
CA17104

n°	Surname	Name	Country	D	Ab	Title
1	BAROUD	Milad	FRANCE	6-8		
2	BASTIAT	Guillaume	FRANCE	6-8		
3	BERTRAND	Philippe	FRANCE	6		
4	BERRAL GONZALEZ	Alberto	SPAIN	6-8	X	Decoding anti-cancer drug structures and nanomolecular associations using GEDA web-tool
5	BONNET	Samuel	FRANCE	6		
6	CLERE	Nicolas	FRANCE	6	X	SPARC protein, an original target to prevent cancer chemoresistance ?
7	DAVID	Stéphanie	FRANCE	6-8	X	Development of lipid-based nanocarriers for the co-delivery of siRNA anti-survivin and Lapatinib for HER2 breast cancer treatment
8	DE LAS RIVAS	Javier	SPAIN	6-8	X	*Introduction of WG2 meeting*
9	DHUMAL	Dinesh	FRANCE	6-8	X	Self-assembling dendrimer nanosystems for drug delivery in treating and detecting drug-resistant cancers
10	DOGAN	Soner	TURKEY	6-8	X	The effects of different types of calorie restriction on multiple drug resistance genes related mirnas in mammary tissue of breast cancer mouse model
11	DURAK	Umut	TURKEY	6-8		Synthesis and characterization of therapeutic antibody-drug conjugates against ovarian cancer
12	ERDOGAN	Duygu	TURKEY	6-8	X	
13	FORNAGUERA	Cristina	SPAIN	6	X	Use of extracellular vesicles as mRNA delivery systems
14	FRANCONI	Florence	FRANCE	6-8		
15	IDLAS	Pierre	FRANCE	6-8		
16	LADAYCIA	Abdallah	FRANCE	6-8		
17	LEMAIRE	Laurent	FRANCE	6-8		
18	LEPELTIER	Elise	FRANCE	6-8		
19	MAUCERI	Matteo	ITALY	6	X	Pin1: a promising target for High-Grade Serous Ovarian Cancer
20	MORILLE	Marie	FRANCE	6-8		
21	MOURATO	Ana	PORTUGAL	6-8		
22	PASSIRANI	Catherine	FRANCE	6-8		
23	PUXXEDU	Michela	ITALY	6	X	A novel class of pyrrole derivatives as anti-glioblastoma and anti-chronic myeloid leukemia agents
24	RIJO	Patricia	PORTUGAL	6-8	X	Self-assembly nanoparticles of bioactive royleanones
25	RIZZOLIO	Flavio	ITALY	6		
26	SAULNIER	Patrick	FRANCE	6-8	X	*Presentation of MINT laboratory - Angers*
27	SILVESTRI	Romano	ITALY	6		
28	VESSIERES	Anne	FRANCE	6		

Remote persons presenting :

n°	Surname	Name	Country	D	Ab	Title
1	LAWSON	Dale	ITALY	6	X	*Presentation of COST new rules*
2	MOHR	Thomas	AUSTRIA	6	X	*NANODB - Nanoparticle related -omics data in ArrayExpress and Gene Expression Omnibus*
3	HADJIKAKOU	Sotiris	GREECE	6	X	Combination of antibiotics with metal ions in one entity for targeted chemotherapy of human breast cancer
4	DOMINGUEZ-ALVAREZ	Enrique	SPAIN	6	X	Selenocompounds evaluation as novel MDR-reversing anticancer agents
5	ABATEMATTEO Carmen Abate	Francesca Serena	ITALY	6	X	Multifunctional sigma receptors ligands chelating metals against MDR tumors
6	O'BOYLE	Niamh	IRELAND	6	X	Pyrazinib as a radiosensitizer and its phosphate produg
7	TOSHEVA Yordan	Aleksandra	BULGARIA	6	X	Biocompatible chitosan-alginate nanoparticles co-loaded with doxorubicin and quercetin – a new approach for enhancing doxorubicin efficacy
8	POPOVTZER	Rachela	ISRAEL	6	X	The golden era of nanoparticles: theranostics, stratification and personalized medicine
9	MAC CARTHY	Florence	IRELAND	6	X	New chemical probes affecting cancer cell growth and eliciting molecular target and phenotypic responses. Focus on indole and quinoline.